SLC43A2: A Potential Drug Target and Biomarker for Diseases (G124935)

Target Name: SLC43A2

NCBI ID: G124935

SLC43A2

SLC43A2: A Potential Drug Target and Biomarker for Diseases

SLC43A2, also known as SLC43A2 gene, is a member of the SLC43 family, which is responsible for transmitting genetic information across cell lines. SLC43A2 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

The SLC43A2 gene is located on chromosome 16, and its encoded protein is a member of the SLC43 family, which is characterized by the presence of a unique transmembrane region and a N-terminal extracellular domain. The SLC43A2 protein is made up of 43 amino acid residues and has a calculated molecular weight of 51.1 kDa.

SLC43A2 is expressed in various tissues and cells of the body, including the brain, heart, liver, and pancreas. It is also highly expressed in cancer tissues, which makes it a potential drug target for cancer therapies.

SLC43A2 has been shown to be involved in various cellular processes, including cell signaling, DNA replication, and metabolism. It is a transcription factor that has been shown to promote the expression of various genes, including cyclin D1, p21, and p53. SLC43A2 has also been shown to play a role in the regulation of DNA replication, which is critical for cell growth and division.

In addition to its role in cell signaling and DNA replication, SLC43A2 has also been shown to be involved in metabolism. It has been shown to be involved in the regulation of glucose metabolism, which is critical for maintaining energy homeostasis in the body. SLC43A2 has also been shown to play a role in the regulation of lipid metabolism, which is important for maintaining cellular membrane structure and function.

SLC43A2 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. For example, studies have shown that inhibiting SLC43A2 can lead to a reduction in the growth and survival of cancer cells. Additionally, SLC43A2 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells.

In addition to its potential as a drug target and biomarker, SLC43A2 has also been shown to have potential clinical applications. For example, studies have shown that SLC43A2 can be used as a potential therapeutic agent for treating cancer by inhibiting its expression. Additionally, SLC43A2 has been shown to be involved in the regulation of glucose and lipid metabolism, which could make it a potential therapeutic target for diseases characterized by these processes, such as diabetes and metabolic heart disease.

In conclusion, SLC43A2 is a member of the SLC43 family that is responsible for transmitting genetic information across cell lines. It has been shown to be involved in various cellular processes, including cell signaling, DNA replication, and metabolism. SLC43A2 has also been shown to play a role in the regulation of DNA replication and metabolism, which makes it a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Further research is needed to fully understand the role of SLC43A2 in disease progression and the development of new therapeutic approaches.

Protein Name: Solute Carrier Family 43 Member 2

Functions: Uniporter that mediates the transport of the stereospecific L-phenylalanine, L-methionine and L-branched-chain amino acids, between the extracellular space and the cytoplasm and may control the transepithelial (re)absorption of neutral amino acid in kidney and small intestine (PubMed:30379325, PubMed:15659399). The transport activity is mediated through facilitated diffusion and is sodium ions-, chloride ions- and pH-independent (PubMed:15659399)

The "SLC43A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC43A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets